SHIBA Aya

シバアヤ | SHIBA Aya

Affiliation and department：
Job title： Associate Professor

Research field (2)： Experimental pathology , Human pathology

Research theme for competitive and other funds (11)：

2023 - 2025 Stratifinを標的とした新規PPI阻害剤の肺腺癌治療薬としての開発
2022 - 2025 Elucidation of mechanisms of carcinogenesis, metastasis, and metabolism based on histological characteristics of HNF4alpha-positive lung adenocarcinoma
2023 - 2024 エネルギー代謝リプログラミングに着目したRET阻害薬獲得耐性分子メカニズムの解明
2021 - 2024 肺腺癌細胞においてミトコンドリアに局在するOCIAD2の機能的意義の検証
2019 - 2021 SFN阻害を基盤としたEGFR阻害薬獲得耐性克服戦略の解析

Show all

Papers (42)：

Aya Shiba-Ishii, Takayuki Isagawa, Toshihiro Shiozawa, Naoko Mato, Tomoki Nakagawa, Yurika Takada, Kanon Hirai, Jeongmin Hong, Anri Saitoh, Norihiko Takeda, et al. Novel therapeutic strategies targeting bypass pathways and mitochondrial dysfunction to combat resistance to RET inhibitors in NSCLC. Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease. 2024. 167249-167249
Hitomi Kawai, Tamaki Miura, Natsumi Kawamatsu, Tomoki Nakagawa, Aya Shiba-Ishii, Taichiro Yoshimoto, Yusuke Amano, Atsushi Kihara, Yuji Sakuma, Kazutaka Fujita, et al. Expression patterns of HNF4α, TTF-1, and SMARCA4 in lung adenocarcinomas: impacts on clinicopathological and genetic features. 2024
Aya Shiba-Ishii, Noriko Takemura, Hitomi Kawai, Daisuke Matsubara. Histologic transformation of non-small-cell lung cancer in response to tyrosine kinase inhibitors: Current knowledge of genetic changes and molecular mechanisms. Cancer Science. 2024
Teruyama, Fumiya, Kuno, Akihiro, Murata, Yoshihiko, Nakagawa, Tomoki, Shiba-Ishii, Aya, Yuguchi, Shu, Noguchi, Masayuki. Mutational landscape of primary breast angiosarcoma with repeated resection and recurrence over a 15-year period: A case report. PATHOLOGY INTERNATIONAL. 2022. 72. 9. 457-463
Shiba-Ishii, Aya, Johnson, Ted, Dagogo-Jack, Ibiayi, Mino-Kenudson, Mari, Johnson, Theodore R, Wei, Ping, Weinrich, Scott L, McTigue, Michele A, Walco, et al. Analysis of lorlatinib analogs reveals a roadmap for targeting diverse compound resistance mutations in ALK-positive lung cancer. Nature cancer. 2022. 3. 6. 710-722

ｍore...

MISC (2)：

吉田勤, 南優子, 柴綾, 中里宜正, 野口雅之. 肺腺癌症例におけるGOLM1遺伝子発現の特徴. 日本病理学会会誌. 2011. 100. 1. 306-306
橘啓盛, 南優子, 柴綾, 吉田勤, 中里宜正, 佐藤幸夫, 呉屋朝幸, 野口雅之. 小型肺腺癌におけるMET遺伝子コピー数とHepatocyte growth factor、MET発現解析. 肺癌. 2010. 50. 5. 514-514

Patents (2)：

抗がん剤
抗がん剤

Books (2)：

医学のあゆみ Vol.277 No.12
医歯薬出版 2021
病理と臨床
2011

Lectures and oral presentations (16)：

Analysis of lorlatinib analogs reveals roadmap for targeting compound resistance mutations in ALK-positive lung cancer
(第81回日本癌学会学術総会)
スフェロイド、オルガノイド、ゼノクラフトを用いた肺癌研究
(第62回日本肺癌学会学術集会)
浸潤部にのみFGFR T790M遺伝子変異が認められた、L858R遺伝子変異肺腺癌の1例
(第58回日本肺癌学会学術集会 2018)
Stratifin Regulates Stabilization of Receptor Tyrosine Kinases via Activation of Ubiquitin-Specific Protease 8 in Lung Adenocarcinoma.
(IASLC第18回世界肺癌学会議 2017)
SFN Stabilizes Oncoproteins through Binding with SKP1 to Block SCF<Sup>FBW7</Sup> Ubiquiting Ligase.
(IASLC第18回世界肺癌学会議 2017)

ｍore...

Professional career (1)：

博士(医学) (筑波大学)

Work history (5)：

2022/03 - 現在 University of Tsukuba Faculty of Medicine Associate Professor
2021/04 - 2022/02 筑波大学附属病院
2019/04 - 2021/03 日本学術振興会海外特別研究員(RRA)
2019/04 - 2021/03 Massachusetts General Hospital Cancer Center Research Fellow
2013/04 - 2019/03 University of Tsukuba Faculty of Medicine Assistant Professor

Awards (5)：

2023/10 - 日本癌学会 Woman scientists plenary symposium award
2023/10 - 日本癌学会日本癌学会奨励賞
2019/11 - 日本病理学会日本病理学会学術奨励賞
2018/09 - TIDE Women’s Award
2012/03 - 筑波大学人間総合科学研究科優秀論文賞

※ Researcher’s information displayed in J-GLOBAL is based on the information registered in researchmap. For details, see here.

Return to Previous Page